Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person…
Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills,…
In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader,…
Sanofi’s Country Lead, President & Managing Director for Italy Marcello Cattani discusses his career track and explains the company’s broad manufacturing footprint in the country – where Sanofi has four…
Luca Benatti, one of Italian biotech’s most notable entrepreneurs, outlines some of the key challenges of starting a biotech company in Europe, highlights how these barriers can be overcome, and…
Serial bioentrepreneur Luca Benatti introduces EryDel, an Italian firm based on the concept of using a patient’s red blood cells to deliver drugs. Benatti also weighs in on the strengths…
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over…
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and…
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
See our Cookie Privacy Policy Here
